Completed PHASE3 INTERVENTIONAL 2-arm NCT06544551

Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

Sponsor: Beijing Kawin Technology Share-Holding Co., Ltd.

Conditions Chronic Hepatitis B Virus Infection

Interventions Peginterferon Alfacon-2 Peginterferon Alfacon-2 placebo

Updated 1 time since 2024 Last updated: Aug 5, 2024 Started: Dec 28, 2021 Primary completion: Nov 30, 2023 Completion: Dec 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Hepatitis B Virus Infection and is currently completed. Beijing Kawin Technology Share-Holding Co., Ltd. leads this study, which shows 1 recorded version since 2021 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

1 version recorded

Completed — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Kawin Technology Share-Holding Co., Ltd.

Data source: Beijing Kawin Technology Share-Holding Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chizhou, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Harbin, China , Heze, China and 15 more locations